Search
phenylbutyrate (Buphenyl, Olpruva)
Indications:
- used to treat urea cycle disorder by facilitating clearance of ammonia
- shows promise in treatment of diabetes mellitus type 2
Dosage:
- oral dose based on size: < 20 grams (40 tablets)/day
- given in divided doses 3-6 times/day with meals
Tablets: 500 mg
Adverse effects:
- common
- change in frequency of breathing
- irregular menstruation
- low back pain
- stomach pain
- mood or mental changes
- myalgia, muscle twitching
- nausea, vomiting
- nervousness or restlessness
- pedal edema
- dysgeusia
- fatigue or weakness
- less common
- fever, chills
- arthralgia
- sore throat
- unusual bleeding or bruising
- rare
- seizures
- dizziness
- dryness of the mouth
- palpitations
- hypertension
- increased thirst
- irritability
- muscle cramps
- rectal bleeding
- swelling of the face
- unusual weight gain
- weak pulse
Mechanism of action:
- improves peripheral insulin sensitivity & glucose oxidation [3]
General
carboxylate
metabolic agent (metabolic modifier)
Database Correlations
PUBCHEM cid=5258
References
- Drugs.com
http://www.drugs.com/cons/buphenyl.html
- sodium phenylbutyrate (Rx)
Medscape
https://reference.medscape.com/drug/buphenyl-phenylbutyrate-sodium-342814
- Zoler ML
New Type 2 Diabetes Treatment Shows Promise in First Human Study.
Medscape. November 18, 2021
https://www.medscape.com/viewarticle/963229
Component-of
sodium phenylbutyrate/tauroursodeoxycholic acid; sodium phenylbutyrate/taurursodiol (Relyvrio, AMX0035)